BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 16848724)

  • 1. Targeted therapies in gynecologic cancers.
    Chon HS; Hu W; Kavanagh JJ
    Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
    Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
    Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Targeted therapy for locally advanced and/or metastatic bladder cancer].
    Wallerand H; Robert G; Bernhard JC; Ravaud A; Ferrière JM
    Prog Urol; 2008 Jul; 18(7):407-17. PubMed ID: 18602599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metastatic breast cancer--new methods of treatment].
    Rack B; Heinemann V; Schindlbeck C; Walther J; Salat C; Sommer H
    MMW Fortschr Med; 2008 Jan; 150(1-2):34-6. PubMed ID: 18300641
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent development of molecular-targeted drugs in lung cancer.
    Saijo N; Kenmotsu H
    Intern Med; 2010; 49(18):1923-34. PubMed ID: 20847494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular targets in colon cancer].
    Borner MM
    Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeted therapies. New hopes, new challenges].
    Barlési F
    Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
    [No Abstract]   [Full Text] [Related]  

  • 11. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to HER family targeting antibodies.
    Kruser TJ; Wheeler DL
    Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
    Fartoux L; Desbois-Mouthon C; Poupon R; Rosmorduc O
    Gastroenterol Clin Biol; 2006 Oct; 30(10):1133-5. PubMed ID: 17075466
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
    Kim R; Toge T
    Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factors and their receptors: new targets for prostate cancer therapy.
    Barton J; Blackledge G; Wakeling A
    Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
    Wheeler DL; Dunn EF; Harari PM
    Nat Rev Clin Oncol; 2010 Sep; 7(9):493-507. PubMed ID: 20551942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of breast cancer with molecular targeting agents.
    Gasparini G; Longo R; Torino F; Morabito A
    Ann Oncol; 2005 May; 16 Suppl 4():iv28-36. PubMed ID: 15923426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond Herceptin and Gleevec.
    Fischer OM; Streit S; Hart S; Ullrich A
    Curr Opin Chem Biol; 2003 Aug; 7(4):490-5. PubMed ID: 12941424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.
    Taylor K; Micha D; Ranson M; Dive C
    Expert Opin Investig Drugs; 2006 Jun; 15(6):669-90. PubMed ID: 16732718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.